Grant: Collaborative Health Research Projects
McGill University
$65,750.00
New molecular magnetic resonance imaging (mMRI) contrast agents for imaging of Cathepsin B
FY 2010-11
Summary
Cathepsin B (CatB), a cysteine protease, is known to be associated with numerous pathological conditions of the central nervous system (CNS), including brain tumours (e.g. gliomas) and Alzheimer's disease (AD). In gliomas, CatB plays a major role in tumour invasion through degradation of the extracellular matrix. As such, a large number of CatB inhibitors are actively being developed as anti-cancer agents, including targeted therapies based on enzyme-activated prodrug strategies. In AD, CatB is thought to play anti-amyloidogenic and neuroprotective functions. As such, pharmacological agents which increase the expression of CatB have the potential to counteract AD neuropathology. In both glioma and AD, measuring the expression and/or activity of CatB is crucial for the proper assessment the therapeutic efficacy of new agents. While traditional measures of changes in enzyme expression/activity in response to therapeutic intervention, such as enzyme histochemistry and immunohistochemistry on tissue sections, are feasible for animal models, these methods are not practical in human subjects. As such, methods to monitor enzyme expression/activity in a non-invasive fashion are required. In this proposal, we plan to develop novel CatB-activated molecular MRI probes and to subsequently evaluate these probes in rodent models of glioma and AD. This proposed project is truly multi-disciplinary and will seamlessly combine the expertise from Dr. Scott Bohle's lab (McGill Department of Chemistry) for the design, synthesis, and chemical characterization of the probes, Dr. Edith Hamel's lab (Department of Neurology and Neurosurgery, Montreal Neurological Institute/McGill University) for the ex vivo evaluation of probe activity as well as in vivo evaluation in mouse models of AD, and Dr. Barry Bedell's lab (Small Animal Imaging Lab, Montreal Neurological Institute/McGill University) for the development of MRI techniques for CatB probe evaluation in rodent models of glioma and AD.
Program
Collaborative Health Research Projects
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
351032-2008
Name nom
Bedell, Barry
Department département
Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2008
Award amount
65750
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Partie
3
Nb partie
3
Application title
New molecular magnetic resonance imaging (mMRI) contrast agents for imaging of Cathepsin B
Keyword
NSERC
Application summary
Cathepsin B (CatB), a cysteine protease, is known to be associated with numerous pathological conditions of the central nervous system (CNS), including brain tumours (e.g. gliomas) and Alzheimer's disease (AD). In gliomas, CatB plays a major role in tumour invasion through degradation of the extracellular matrix. As such, a large number of CatB inhibitors are actively being developed as anti-cancer agents, including targeted therapies based on enzyme-activated prodrug strategies. In AD, CatB is thought to play anti-amyloidogenic and neuroprotective functions. As such, pharmacological agents which increase the expression of CatB have the potential to counteract AD neuropathology. In both glioma and AD, measuring the expression and/or activity of CatB is crucial for the proper assessment the therapeutic efficacy of new agents. While traditional measures of changes in enzyme expression/activity in response to therapeutic intervention, such as enzyme histochemistry and immunohistochemistry on tissue sections, are feasible for animal models, these methods are not practical in human subjects. As such, methods to monitor enzyme expression/activity in a non-invasive fashion are required. In this proposal, we plan to develop novel CatB-activated molecular MRI probes and to subsequently evaluate these probes in rodent models of glioma and AD. This proposed project is truly multi-disciplinary and will seamlessly combine the expertise from Dr. Scott Bohle's lab (McGill Department of Chemistry) for the design, synthesis, and chemical characterization of the probes, Dr. Edith Hamel's lab (Department of Neurology and Neurosurgery, Montreal Neurological Institute/McGill University) for the ex vivo evaluation of probe activity as well as in vivo evaluation in mouse models of AD, and Dr. Barry Bedell's lab (Small Animal Imaging Lab, Montreal Neurological Institute/McGill University) for the development of MRI techniques for CatB probe evaluation in rodent models of glioma and AD.